Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2011

View Archived Issues

Interim phase I data on E-7080 in hepatocellular carcinoma disclosed at ILCA meeting

FDA advisory committee to review rivaroxaban NDA following ROCKET AF study

Bayer discloses preclinical data on dual vasopressin V1A/V2 receptor antagonist

Long-term therapy with cysteamine eye drops assessed in subjects with cystinosis

Aeterna Zentaris selective ERK-1/ERK-2 inhibitor shows anticancer activity in vivo

Novel biocrea phosphodiesterase 2 inhibitor has procognitive effects

High Point Pharmaceuticals claims new heme oxygenase 1 production inducers and/or activity enhancers

Transgene Biotek develops new recombinant therapeutic for liver cancer

GSK receives BARDA contract to develop boron-based antibiotic

New microRNA-based therapies disclosed by University of Miami

Novel SsIR-based vaccines created against nematode infection

Okayama University claims new iodobenzyl-bleomycin analogues

TWi Biotechnology completes enrollment in phase IIb AC-201 trial

Phase II MG-01CI trial meets primary endpoints

BHR Pharma advances phase III SyNAPSe trial

Topline phase IIIb data on Xiaflex in Dupuytren's contracture with multiple palpable cords

ImmunoCellular Therapeutics updates on phase II ICT-107 trial

FDA clears Fujirebio immunoassay for use in ROMA algorithm to determine ovarian cancer risk

Zytiga approved in Europe

Debiopharm and Ascenta Therapeutics announce exclusive license agreement for AT-406

Prespecified number of events reached for unblinding of Exelixis' EXAM trial

Verona Pharma's VRP-700 significantly reduces coughing in Italian study

Novartis gains E.U. approval for Votubia

Takeda advances DPP IV inhibitor into Japanese phase III trials in type 2 diabetes

FDA updates boxed warning for all TNF-alpha inhibitors

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026